Octreotide Acetate Injection

Used for emergency treatment of esophageal gastric variceal bleeding caused by cirrhosis, usually combined with special treatments such as endoscopic sclerotherapy. Due to impaired liver function and increased pressure in the portal vein system, patients with cirrhosis are prone to esophageal gastric variceal rupture and bleeding. Acetate octraotide injection plays an emergency role in stopping bleeding and preventing rebleeding by reducing portal vein pressure.

Complications such as pancreatic fistula and intestinal fistula may occur after pancreatic surgery. Acetate octreotide injection can reduce digestive fluid secretion, promote fistula healing, and reduce the risk of complications. Generally, 0.1mg subcutaneous injection is used, three times a day, for a continuous treatment of 7 days. The first injection should be given at least 1 hour before surgery.

For acute pancreatitis, especially in its early stages, octreotide acetate injection can quickly control the condition and alleviate clinical symptoms. It can inhibit the basal secretion and stimulated secretion of the pancreas, suppress the activity of pancreatic enzymes and phospholipase A2, reduce the pressure inside the pancreatic duct, eliminate toxins that cause necrosis, stimulate the reticuloendothelial system, enhance the activity of the mononuclear phagocytic cell system, control the cascade reaction induced by cytokines, thereby protecting pancreatic cells and preventing the progression of pancreatic lesions in acute pancreatitis.

It can significantly alleviate a wide range of clinical symptoms and physical signs closely associated with functional gastrointestinal and pancreatic neuroendocrine tumors. Abundant clinical trial data and real-world research evidence fully demonstrate that this pharmaceutical product delivers reliable therapeutic efficacy against multiple common subtypes of such hormone-secreting tumors.

Patients with carcinoid tumors often experience carcinoid syndrome, manifested as facial flushing, diarrhea, asthma, and other symptoms. Acetate octraotide injection can alleviate these symptoms by regulating the secretion of relevant hormones.

VIP tumor patients secrete large amounts of vasoactive intestinal peptide, leading to severe diarrhea, hypokalemia, etc. This drug can effectively inhibit the secretion of vasoactive intestinal peptide and improve patient symptoms.

Patients diagnosed with malignant glucagonoma will suffer from sustained excessive secretion of glucagon into systemic circulation, triggering a series of typical clinical symptoms including secondary diabetes mellitus and characteristic necrolytic migratory erythema skin lesions. Injectable octreotide acetate is capable of markedly lowering abnormally elevated plasma glucagon concentrations and effectively relieving the full spectrum of disease-related clinical manifestations.

Usually combined with selective H2 receptor antagonists, and antacids may be added as appropriate. Patients with gastrinoma have excessive secretion of gastrin, which stimulates gastric acid secretion and leads to digestive ulcers and other diseases. Acetate octreaotide injection can inhibit gastrin secretion, reduce gastric acid production, and promote ulcer healing.

It is clinically applied for preoperative prevention of severe hypoglycemia and long-term maintenance of stable normal blood glucose levels in patients suffering from pancreatic islet cell tumors. Individuals diagnosed with insulinoma frequently face uncontrolled excessive insulin secretion accompanied by obvious hypoglycemia-related clinical manifestations. This therapeutic injection can potently suppress abnormal insulin over-secretion and effectively avoid the sudden onset of hypoglycemic episodes.

It can effectively inhibit the abnormal secretion of growth hormone-releasing factor, significantly lower excessively elevated serum growth hormone levels, and gradually relieve various uncomfortable clinical symptoms caused by hormone disorder.

For patients with acromegaly who have failed surgery, radiation therapy, or dopamine receptor agonist therapy, symptoms can be controlled by reducing the concentration of growth hormone (GH) and growth hormone mediator C. It is also applicable to patients with acromegaly who are unable or unwilling to undergo surgery, as well as patients in the interval period where radiation therapy has not yet taken effect. By inhibiting the secretion of growth hormone, patients can improve symptoms.